Jeremy Levin, former CEO of Physiome Sciences, is now global head of strategic alliances for the Novartis Institutes for Biomedical Research. Levin left Physiome in April. According to Physiome’s website, the company is undergoing an “offer period for its currently contemplated corporate transaction.” Company officials were unable to provide further information prior to press time.
Two former Molecular Mining executives have landed new positions: Justin Lancaster, vice president for business development at Molecular Mining prior to the company’s closure in March, is now executive vice president of business development at biotech incubator CalbaTech. Meanwhile, Don Van Dyke, formerly vice president of sales and marketing at Molecular Mining, has launched a consulting firm called Bioscience Market Access Associates to assist emerging biotech companies with sales, marketing, and commercialization.
Caroline Kovac, general manager of IBM Life Sciences, is one of nine members of the newly formed advisory board for Colorado’s Office of Life Sciences and Biotechnology.
Cognia has appointed John Chiplin as chairman of its board of directors. Chiplin will succeed Cognia co-founder, John Wilkerson, who will remain on the board and will continue to act as a consultant. Chiplin was previously president and CEO of GeneFormatics, which recently merged with Structural Bioinformatics to form Cengent Therapeutics.